3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
31
Melanoma
2
Lymphedema
2
Lymphatic Metastasis
2
Breast Cancer Lymphedema
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Margins of Excision
1
Invasive Breast Cancer
1
Inflammatory Breast Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Anus Neoplasms
1
Interventions
pembrolizumab
3
talimogene laherparepvec
1
spartalizumab
1
nanocis
1
fludarabine
1
avelumab
1
atezolizumab
1
aldesleukin
1
Technetium-99
1
TTI-621
1
Radiation
1
Proton Pump Inhibitors
1
Nivolumab
1
Lasers
1
Ipilimumab
1
Interleukin-2
1
Infracyanine green
1
Indocyanine Green
1
Hydrocortisone
1
Cyclophosphamide
1
Bleomycin
1
Antineoplastic Protocols
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
Indocyanine Green
×
Breast
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled